Abstract. The vitronectin receptor (ot~B3) is a member of the integrin superfamily of adhesive protein receptors that mediate a wide spectrum of adhesive cellular interactions, including attachment to vitronectin, yon WiUebrand factor, fibrinogen, and thrombospondin. We have studied the binding of fibronectin to the purified vitronectin receptor, and the role of this receptor in the attachment of cells to fibronectin. A solid-phase microtiter assay was developed to investigate the binding properties of the vitronectin receptor. Purified tx433 bound fibronectin with high affinity in a saturable, divalent cation-dependent manner. Binding was inhibited by soluble vitronectin, by RGD-containing peptides, and by LM609, a monoclonal antibody against the vitronectin receptor known to inhibit the binding of adhesive proteins to Otvfl3. Immunoinhibition experiments showed that M21 human melanoma cells, which express the fibronectin receptor, aSfll, as well as art3, used both of these integrins to attach and spread on fibronectin. In support of this finding, M21-L cells, a variant cell line that specifically lacks tXvfl3 but expresses otv/31, attached and spread poorly on fibronectin. In addition, otv~ from surface-labeled M21 cells was retained, and selectively eluted by RGDS from a fibronectin affinity column. These results indicate that o~B3 acts in concert with ot5/3~ in promoting fibronectin recognition by these cells. We conclude that fibronectin binds to the otvfl3 vitronectin receptor specifically and with high affinity, and that this interaction is biologically relevant in supporting cell adhesion to matrix proteins.
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T I-IE vitronectin receptor (oLvB3) is a member of a superfamily of receptors known as the integrins (Hynes, 1987) , which mediate a broad spectrum of cell-cell and cell-substrate interactions. It is now appreciated that such apparently diverse phenomenon as platelet aggregation (Phillips et al., 1980) , endothelial cell adhesion to matrix proteins (Charo et al., 1987; Cheresh, 1987) , embryogenesis (Duband et al., 1988) , and perhaps tumor cell metastasis (Humphries et al., 1986) are mediated by structurally and/or immunologically related integrin receptors expressed on the cell surface.
Integrins are heterodimer complexes of noncovalently associated or-and/5-subunits. The integrin superfamily can be divided into subfamilies based on the presence of at least five homologous/~-subunits that can associate with one or more ot-subunits. The spectrum of ligands bound to each receptor is dictated by the specific o~-and/3-subunit pairing of the beterodimer complex. For example, cts/3~ shows a very specific ligand recognition capability and appears to bind only fibronectin, whereas endothelial cell otzOl is a more promiscuous receptor and binds both laminin and collagen (Elites and Hemler, 1989; Kirchhofer et al., 1990) . In addition, a given cell may express two or more integrins that bind the same adhesive proteins. The ligand binding specificity of the vitronectin receptor has been unclear. Pytela et al. (1986) found that the vitronectin receptor reconstituted into phospholipid vesicles composed of phosphatidyl choline bound to vitronectin-, but not fibronectin-, fibrinogen-, or thrombospondin-coated surfaces. Subsequent studies found that two different monoclonal antibodies that react with ot,/33 blocked the adhesion of human umbilical vein endothelial cells to yon W'dlebrand factor (vWf) 1 and fibrinogen, suggesting that otvB3 interacted with these adhesive proteins as well. Neither of these antibodies blocked the adhesion of endothelial cells, which express both otv/33 and cts#~, to fibronectin (Charo et al., 1987; Cheresh, 1987) . Recently, Conforti et al. (1990) found that otv~3 reconstituted into phosphatidyl choline vesicles bound only vitronectin, in agreement with the earlier work of Pytela, and that when a mixture of phosphatidyl serine and phosphatidyl choline was used to form the vesicles o~,B3 also bound vWf and fibronectin. It was not determined, however, whether ot,B3 in intact cells bound these adhesive proteins, or if this binding was involved in adhesive cellular interactions.
In this paper we present evidence that purified cx;B3 is capable of recognizing fibronectin in a specific and RGDdependent manner, and that it and the fibronectin receptor, o~sB~, act in concert in mediating the attachment and spreading of human melanoma cells on a fibronectin substrate. These data provide evidence for a novel biological role for the vitronectin receptor, o~f13, in mediating the adhesion of cells to fibronectin in the extraceUular matrix.
Materials and Methods

Purification of Proteins
The vitronectin receptor (av~3) was purified from human placenta as described (Smith and Cheresh, 1988) . Briefly, one or two fresh human placentas were homogenized in a food processor in the presence of 20 mM Tris-HCl, 150 mM NaCI, 2.0 mM CaCI2, 100 mM octyl-glucopyranoside, 0.05% NAN3, pH 7.5. The homogenates were centrifuged at 100 g to remove the tissue, and again at 10,000 g. The supernat~ts were then passed over an LM609 affinity column to selectively retain the av/33 complex, and eluted with 10 mM acetate, 150 mM NaC1, 0.1% NP-40, 2 mM CaC12, pH 2.5. The eluted material was further purified by chromatography on a wheat germ affinity column (Sigma Chemical Co., St. Louis, MO). We obtained '~1 mg of highly purified c~#3 from each placenta. This material was homogeneous on overloaded SDS-polyacrylamide gels, and did not contain detectable levels of platelet GPIIb-llla when assayed by ELISA.
Human vitronectin was purified from plasma as described (Yatohga et al., 1988) . Briefly, human plasma was clotted in a glass beaker in the presence of proteas¢ inhibitors, and applied to a beparin-Sepharose column in the presence of 8 M urea. Purified vitronectin was eluted with 10 mM Naphosphate buffer (pH 7.7) containing EDTA (5 mM), urea (8 M), and NaCI (0.5 M). Human plasma fibronecfin was purified by gelatin-agarose affinity chromatography as described (Engvall et al., 1978) . Further purification was performed by gel-filtration on a Sephacryl-S-300 (Pharmacia Fine Chemicals, Piscataway, NJ) column equilibrated in 50 mM Tris-HC1, 100 mM NaC1, pH 7.4. Peak fractions were analyzed on reduced SDS-gels, and were free of detectable fibrinogen. Human fibrinogen and vWf were purified as described (Cberesh et al., 1989) .
Antibodies
The c~v~3 monoclonal LM609 was produced as described (Cheresh and Spiro, 1987) . The fibronectin receptor antibody BIIG2 (Werb et al., 1989) was provided by Dr. Caroline Damsky (University of California, San Francisco, CA) and the GPIIb-IIIa monoclonal 10E5 (Coller et al., 1983) was provided by Dr. Barry Coller (State University of New York at Stony Brook, NY).
Biotinylation of Adhesive Proteins
For biotinylation, proteins were dialyzed into 0.1 M NaHCO3, 0.1 M NaCI, pH 8.2 and centrifuged in a table top ultracentrifuge (model TL-100; Beckman Instruments, Inc., Palo Alto, CA) at 100,000 g for 30 min at 4°C to remove any particulate matter, and the protein concentration was adjusted to a concentration of 1 mg/rnl. Sulfo-NHS-Biotln (No. 21217; Pierce Chemical Co., Rockford, IL) was added as a solid (0.2 mg of biotin ester/ml adhesive protein)rand gently mixed on an end-over-end Nutator (Clay Adams, Parsippany, NJ) for 30 rain at room temperature. Unreacted biotin ester was removed by exhaustive dialysis against 50 mM Tris-HCI, 100 mM NaCI, 0.05% NAN3, pH 7.4, at 4°C, and the biotinylated protein was stored at 4°C until used.
Binding Assay
The binding of adhesive proteins to immobilized ~v{/3 was performed using a modification of the method recently described for platelet GPIIb-IIIa (Steiner, B., and P. Hadvary. 1988 Charo et al., 1990) . The vitronectin receptor (1 mg/ml) was diluted 1:200 with a Triton X-100-free buffer containing 20 mM Tris-HCl, 150 mM NaCI, 1 mM CaCI2, 0.02% NAN3, and then immediately added to 96-well microtiter plates (Linbro E.I.A. H Plus Microtitration plate; Flow Laboratories, Inc., McLean, VA) at 0.1 ml (0.5/~g) per well, and incubated overnight at 4°C. Microfiter plates were stored at 4°C for up to 2 mo before being used. At the time of the experiment, the wells were washed once with 50 mM Tris, 100 mM NaC1, 2 mM CaC12, 0.02% NAN3, 1 mg/ml BSA, pH 7.4 (binding buffer) and then incubated in 0.1 ml of a solution of binding buffer with 35 mg/ml BSA for 2 h at 30°C to block nonspecific binding, followed by an additional wash with binding buffer (with 1 mg/ml BSA).
Biotinylated adhesive proteins (0.1 mi/well) were added and incubated for 3 h at 30°C in binding buffer (with 1 mg/ml BSA). After the incubation the wells were aspirated completely and washed once with 250/zl of binding buffer. Bound ligand was quantitated by the addition of 0.1 ml of an antibiotin antibody conjugated to alkaline phosphatase (1:2,000 dilution; Sigma Chemical Co.), followed by a wash with binding buffer and the addition of 100 ~1 of the substrate, p-nitrophenyl phosphate, prepared daily according to the manufacturer's instructions (Biorad Alkaline Phosphate Substrate Kit; Bio-Rad Laboratories, Richmond, CA). The kinetics of the color development were followed using a microtiter plate reader (Molecular Devices, Menlo Park, CA). All reaction rates were determined within the linear range, and all data points represent the mean of quadruplicate determinations. Standard deviations of these quadruplicates were <20%, and often <10% of the mean. Nonspecific binding was measured in every experiment by determining the binding of biotinylated ligands to BSA-coated wells, and also by determining the binding in the presence of RGDS (250/zM) or EDTA (5 mM), and was consistently <10%.
Binding of c~,~3 to Immobilized Fibronectin
Human fibronectin was digested with chymotrypsin (enzyme/substrate ratio of 1:20) to produce the 120-kD cell-binding domain fragment, as described (Pytela et al., 1985a) , which was coupled to cyanogen bromide activated Sepharos¢ (Pharmacia Fine Chemicals). M21 cells were surface labeled using lactoperoxidase-catalyzed iodiuation (Charo et al., 1986) , and lysed with 200 mM n-octyl a-D-glucopyranoside (n-octyl ~-glucoside) in 25 mM TBS. The cell lysate was slowly passed (at room temperature) over the 120-kD affinity column equilibrated in TBS (pH 7.4) with 50 mM octylglucoside and 2 mM MgC12. It was then washed with the same buffer, and eluted with RGES (1 mg/ml) and then RGDS (1 mg/ml), as described by Pytela et al. (1985a) . Each fraction (0.5 ml) was immunoprecipitated with LM609 (20/~g/ml) and run on reduced 7.5 % SDS-polyacrylamide gels, which were then examined by autoradiography.
Cell Adhesion
M21 and M21-L cells (Cheresh and Spiro, 1987) were grown in RPMI supplemented with 20% (vol/vol) FCS and antibiotics. The cells were partially depleted of methionine by incubation for 2-4 h in RPMI plus PBS-dialyzed serum, and then labeled by incubation with 250/~Ci of [35S]methionine overnight. The cells were then washed three times with serum-free media, harvested, and added to vitronectin-coated microtiter wells. After 30-60 rain at 37°C (in the presence or absence of antibodies) the cells were washed three times and solubilized (0.1 M NaOH, 60 rain, room temperature). Bound cells were quantitated by counting beta emissions. In the control wells ,~50% of the added cells attached to the adhesive protein. Adhesion of cells to BSA-coated wells was <5 % of the adhesion to vitronectin. All measurements were performed in triplicate (or quadruplicate), and the standard deviations were 10% of the mean or less.
Results
Ligand Binding to the Purified Vitronectin Receptor (a,B~)
To investigate the ligand binding properties of avO3 a solidphase microtiter assay was developed. In this assay purified c~J~3 was immobilized on the bottoms of microtiter wells, and biotinylated adhesive protein ligands were added and incubated with the receptor. As seen in Fig. 1 , there was high affinity, saturable binding of vitronectin, fibronectin, vWf, and fibrinogen to the purified vitronectin receptor. In contrast, there was little or no binding of laminin or BSA to
The binding of biotinylated adhesive proteins to av~3 was specific. Fibronectin and vitronectin binding to avfl3 was blocked by a monoclonal antibody (LM609) known to inhibit the binding of cells to vitronectin (Cheresh and Spiro, 1987) , but not by monoclonals to the fibronectin receptor (BIIG2) or to the platelet GPHb-HIa complex 00E5) ( Adhesive Proteins (p_g/ml) Figure I . Binding of adhesive proteins to the purified vitronectin receptor (~v~3). Biotinylated adhesive proteins were added at the indicated concentrations to microtiter wells coated with purified c~d53, and incubated for 3 h at 30°C. After unbound ligand was removed by washing, the bound adhesive protein was determined by ELISA. Data points shown are the mean of quadruplicate determinations.
2). As expected for a member of the integrin superfamily of receptors, chelation of divalent cations with EDTA also completely blocked binding. In addition, binding was blocked by the tetrapeptide RGDS, but not by RGES (not shown). The dodecapeptide from the gamma chain of fibrinogen (amino acids 400-411) did not block fibronectin or vitronectin binding to O~v/~3, although it is known to block the binding of adhesive proteins to GPII'b-HIa on activated platelets (Kloczewiak et al., 1984) . The binding of vWf and fibrinogen to otv/~3 was examined with the same antibodies and peptides, and the results were exactly as found for fibronectin and vitronectin (data not shown). Thus, immobilized O/v/~3 binds adhesive proteins with the properties expected of the cellular vitronectin receptor. The binding of vitronectin and fibronectin to otd33 was mutually exclusive. Fibronectin blocked the binding of biotinylated vitronectin (15 nM) to otd33, and half-maximal inhibition was achieved at a fibronectin concentration of 25 nM, which was comparable to the concentration of vitronectin required to inhibit this binding (Fig. 3) . Similarly, vitronectin very effectively blocked the binding of fibronectin to av/~3 (data not shown). These results indicate that fibronectin and vitronectin compete when binding to ad~3, and suggest that vitronectin binds with somewhat higher affinity.
Additional evidence for a specific interaction between c<d33 and fibronectin was obtained by passing the lysate of surface-labeled M21 melanoma cells, which express both the vitronectin receptor (a~/33) and the fibronectin receptor (ot5/3~) ) over a fibronectin affinity column, as described by Pytela et al. (1985b) . The vitronectin receptor was retained on this column, and was eluted by RGDS, but not by RGES (Fig. 4) .
The VRronectin Receptor Is Involved in the Adhesion of Melanoma Cells to Fibronectin
To determine whether the binding of fibronectin to the vitronectin receptor was functionally significant in the context of a cell membrane we examined the adhesion of two related melanoma cell lines to fibronectin-coated surfaces. M21 cells attached and spread well on fibronectin-coated slides (Fig. 5) . M21 cell adhesion to fibronectin was not significantly inhibited by antibodies against the fibronectin receptor (BIlG2) or the vitronectin receptor (LM609), but was blocked by the combination of the two antibodies. This suggested that o~,,~3 and ,v5/~1 were both involved in M21 cell adhesion to fibronectin. To further investigate the role of ~v/~3 in cellular attachment to fibronectin expe "nments were performed with M21-L cells, which is a mutant cell line that specifically lacks otd~3, but expresses normal levels of the Figure 2 . Binding of fibronectin and vitronectin to immobilized ot,#s. Biotinylated fibroneetin (10 riM) or vitronectin (10 riM) was added to miemtiter wells coated with ~v/~3 in the presence or absence of RGDS (100/am), the t~v/33 monoclonal antibody LM609 (10/~g/ml), EDTA (5 raM), the txs/3~ fibroneetin receptor antibody BIIG2 (10/~g/ml), the GPIlb-llla monoclonal antibody 10E5 (10 pg/ml), and the dodeeapeptide (7400-411) from the gamma chain of fibrinogen (200/~M), and incubated for 3 h at 30°C. Binding is expressed as percent of control. Error bars represent the standard deviation of quadruplicate determinations. Rgure 3. Fibronectin blocks the binding of vitronectin to ~vB3. Biotinylated vitronectin (15 riM) was added to microtiter wells coated with c~./~3 in the presence of the indicated concentrations of fibrone~tin or vitroneetin. Vitronectin that bound to ct,/33 was determined by ELISA, as described in Fig. 1 . Adhesion of metabolically labeled M21 and M21-L melanoma cells to fibronectin was measured in the presence or absence of antibodies to the cq~ fibronectin receptor (BIIG2; 20 #g/ml), the ave3 vitronectin receptor (LM609; 20/~g/ml), and peptides GRGDSPK and RGES (300 pM). Very similar results were obtained when each antibody was used at 10/~g/ml. Data is from one of three similar experiments. Figure 4 . Binding of c~v/33 to immobilized fibronectin. Surfacelabeled M21 cells were lysed and passed over a l-m1 column of the 120-kD cell binding domain of fibronectin coupled to Sepharose. After extensive washing the column was eluted with RGES followed by RGDS. Shown is an SDS gel of the eluted fractions (1 ml) immunoprecipitated with LM609. Lame 1, total lysate. The RGES elution was begun at column fraction number 8, and gel lanes 2-4 represent column fractions 10-12. The RGDS elution was begun at column fraction number 13, and gel lanes 5-10 represent column fractions 15-20.
fibronectin receptor (Cheresh and Spiro, 1987; . As shown in Fig. 5 , these cells attached to fibronectin, but were poorly spread. Adhesion of M21-L cells to fibronectin was completely blocked by BIIG2, and as expected, was unaffected by LM609. These results are quantitated in Table I , and indicate that av/5~ acts in concert with c~5/3~ in promoting M21 cell attachment and spreading on fibronectin.
D i s c u s s i o n
In this study we present biochemical and functional evidence that the vitronectin receptor c~vB3, mediates cellular interactions with fibronectin. Using a sensitive and reproducible solid-phase assay we have found specific and high affinity binding of vitronectin, vWf, fibrinogen, and fibronectin to the purified vitronectin receptor. We have further found that av/53 mediated the adherence and spreading of a human melanoma cell line to fibronectin and bound specifically to a fibronectin affinity column. We conclude from these studies that c~vfl3 is a multifunctional receptor that binds at least four RGD-containing adhesive proteins, including fibronectin. Microtiter plates coated with purified receptors provide a simple and rapid method for studying the binding properties of integrins. We have recently used a similar solid-phase assay to identify a peptide derived from GPBIa that inhibits the binding of fibrinogen to the platelet GPllb-ma complex (Charo et al., 1990) . In using this assay we have found that vitronectin, vWf, fibrinogen, and fibronectin bind to otvB3 in a similar manner. The binding of these adhesive proteins to purified cx,B3 was divalent cation dependent, and was inhibited by RGD peptides and a monoclonal antibody known to inhibit vitronectin binding to C~vB3 on whole cells. In contrast, ligand binding to ¢xvB3 was not blocked by the dodecapeptide from the gamma chain of fibrinogen (at concentrations up to 500 #M), which is consistent with recent reports that the dodecapeptide interacts with GPIlb (c~m), and not GPIIIa (/~3) (D'Souza et al., 1990) . In contrast, there was little binding of laminin and no binding of BSA to o~,f13. These results confirm our earlier work (Charo et al., 1987; Cheresh, 1987) that ¢x~/~3 mediated endothelial cell adherence to fibrinogen and vWf, and provide direct evidence that cx~B3 binds fibronectin and other RGD-containing adhesive proteins specifically and with high affinity.
To determine if the binding of fibronectin to C~v/33 had biological implications we examined the adherence of two related melanoma cell lines to fibronectin. Although M21 and M21-L cells express high levels of the fibronectin receptor (astir), it was clear that the M21 cells attached and spread much more readily on fibronectin than did the M21-L cells. This suggested that Otvfl3, which is present on the M21 cells, but not on the M21-L cells, mediated cellular interactions with fibronectin. Antibody inhibition studies using LM609 confirmed this hypothesis. We conclude from this data that the vitronectin receptor binds fibronectin, and that this binding is functionally significant in as much as it mediates cellular attachment and spreading on fibronectin. Thus, o~,B3 acts in concert with otsBt in promoting M21 cell adhesion and spreading on fibronectin.
The vitronectin receptor appears to be a receptor designed to bind the RGD sequence. We have shown that fibronectin, fibrinogen, and vWf, in addition to vitronectin, bind to OtvB3. Lawler et al. (1988) found that ot~B3 binds thrombospondin. Indeed, it is noteworthy that c~B3 was originally purified on an RGD affinity column (Pytela et al., 1985b) , which suggests that this receptor binds RGD in multiple adhesive proteins with high affinity. In contrast, the fibronectin receptor (asflt) interacts exclusively with fibronectin (Pytela et al., 1986) , and thus appears to recognize the RGD sequence only as presented by fibronectin. In a solid-phase assay similar to the one presented in this paper we have found that purified otsfl~ binds fibronectin, but does not bind fibrinogen, vitronectin, or vWf (Charo, I. F., and L. Nannizzi, unpublished observations).
Earlier studies by Pytela et al. (1985a) found that o~sflt was the predominant cellular receptor in MG-63 osteosarcoma cells that bound to the 120-kD fragment of fibronectin immobiliTed on Sepharose. This study did not report the binding of ¢x,fl3 to fibronectin, under conditions very similar to those used in this study, nor did it specifically exclude this interaction. We used immunoprecipitation with LM609 to specifically follow the binding and elution of otvB3 from the fibronectin column, since the electrophoretic mobility of or,t3 and otsfll on SDS gels is very similar. In addition, the high level of expression of exit3 on M21 cells has facilitated the detection of this interaction.
The relaxed ligand binding: specificity of the vitronectin receptor may facilitate the interaction of ~x,fl3 bearing ceils, such as malignant melanoma cells, with multiple proteins in the extraeellular matrix. It is reasonable to speculate, therefore, that o~,B3 may be important in metastases of tumors. In addition, SaviU et al. (1990) have recently reported that opsinization of senescent polymorphonuclear leukocytes by macrophages occurs via the macrophage o~,f13 receptor. Interestingly, opsinlzation was inhibited by soluble fibronectin as well as by soluble vitronectin. The interaction between fibronectin and otvB3 may thus be of considerable physiological significance.
The existence of multiple integrins on a given cell capable of binding collagen (Santoro, 1986; Coller et al., 1989) , fibronectin (Wayner et al., 1989) , and vitronectin (Lam et al., 1989) has been described. However, little data exists as to the possible biological relevance of this phenomenon. In this report we demonstrate that receptors from two subfamilies of the integrin superfamily, the vitronectin receptor avfl3, and the fibronectin receptor otsB~, can act in concert to mediate cell adhesion and spreading on fibronectin.
